430 related articles for article (PubMed ID: 29079637)
21. Renal dysfunction during and after high-dose methotrexate.
Green MR; Chamberlain MC
Cancer Chemother Pharmacol; 2009 Mar; 63(4):599-604. PubMed ID: 18504579
[TBL] [Abstract][Full Text] [Related]
22. High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma.
Widemann BC; Balis FM; Kempf-Bielack B; Bielack S; Pratt CB; Ferrari S; Bacci G; Craft AW; Adamson PC
Cancer; 2004 May; 100(10):2222-32. PubMed ID: 15139068
[TBL] [Abstract][Full Text] [Related]
23. Glucarpidase (carboxypeptidase g2) intervention in adult and elderly cancer patients with renal dysfunction and delayed methotrexate elimination after high-dose methotrexate therapy.
Schwartz S; Borner K; Müller K; Martus P; Fischer L; Korfel A; Auton T; Thiel E
Oncologist; 2007 Nov; 12(11):1299-308. PubMed ID: 18055849
[TBL] [Abstract][Full Text] [Related]
24. Intravenous radiographic contrast administered prior to high-dose methotrexate and subsequent toxicity requiring the use of glucarpidase.
Schultz TE; Lynch AC
J Oncol Pharm Pract; 2019 Jun; 25(4):993-997. PubMed ID: 29651915
[TBL] [Abstract][Full Text] [Related]
25. Methotrexate nephrotoxicity: Novel treatment, new approach.
Iqbal S; Armaghani A; Aiyer R; Kazory A
J Oncol Pharm Pract; 2013 Dec; 19(4):373-6. PubMed ID: 24255083
[TBL] [Abstract][Full Text] [Related]
26. Successful Treatment of Delayed Methotrexate Clearance Using Glucarpidase Dosed on Ideal Body Weight in Obese Patients.
Krüger C; Engel N; Reinert J; Alsdorf W; Fiedler W; Dierlamm J; Bokemeyer C; Langebrake C
Pharmacotherapy; 2020 May; 40(5):479-483. PubMed ID: 32239519
[TBL] [Abstract][Full Text] [Related]
27. Use of glucarpidase (carboxypeptidase-G2) in pediatric cancer patients: 11-year experience of a tertiary center.
Vila R; Rubio-San-Simón A; Zubiaur P; Navares-Gómez M; Gómez-Hernández P; Arce B; Madero L
EJHaem; 2023 Nov; 4(4):1052-1058. PubMed ID: 38024601
[TBL] [Abstract][Full Text] [Related]
28. Reply to: Glucarpidase for the Treatment of Methotrexate-Induced Renal Dysfunction and Delayed Methotrexate Excretion.
Widemann BC
Pediatr Blood Cancer; 2016 Feb; 63(2):366. PubMed ID: 26488622
[No Abstract] [Full Text] [Related]
29. Treatment of methotrexate intoxication with various modalities of continuous extracorporeal therapy and glucarpidase.
Vilay AM; Mueller BA; Haines H; Alten JA; Askenazi DJ
Pharmacotherapy; 2010 Jan; 30(1):111. PubMed ID: 20030480
[TBL] [Abstract][Full Text] [Related]
30. Methotrexate level discrepancy post-glucarpidase: A pediatric case series and review of literature.
Kibby D; Trinkman H
Pediatr Blood Cancer; 2024 Mar; 71(3):e30831. PubMed ID: 38149827
[TBL] [Abstract][Full Text] [Related]
31. Using a lower dose of glucarpidase to reduce plasma levels of methotrexate.
Widemann BC
Clin Adv Hematol Oncol; 2013 May; 11(5):324-5. PubMed ID: 23880720
[No Abstract] [Full Text] [Related]
32. DAMPAned Methotrexate: A Case Report and Review of the Management of Acute Methotrexate Toxicity.
Young A; Beriault D; Jung B; Nikonova A; Abosh D; Lee S; Zaltzman J; Perl J
Can J Kidney Health Dis; 2019; 6():2054358119895078. PubMed ID: 31903191
[TBL] [Abstract][Full Text] [Related]
33. Glucarpidase for the Treatment of Methotrexate-Induced Renal Dysfunction and Delayed Methotrexate Excretion.
Meyers PA
Pediatr Blood Cancer; 2016 Feb; 63(2):364. PubMed ID: 26488216
[No Abstract] [Full Text] [Related]
34. Fixed-Dose Glucarpidase for Toxic Methotrexate Levels and Acute Kidney Injury in Adult Lymphoma Patients: Case Series.
Truong H; Leung N
Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):e497-e502. PubMed ID: 33563580
[No Abstract] [Full Text] [Related]
35. A prospective study of a simple algorithm to individually dose high-dose methotrexate for children with leukemia at risk for methotrexate toxicities.
Foster JH; Thompson PA; Bernhardt MB; Margolin JF; Hilsenbeck SG; Jo E; Marquez-Do DA; Scheurer ME; Schafer ES
Cancer Chemother Pharmacol; 2019 Feb; 83(2):349-360. PubMed ID: 30488179
[TBL] [Abstract][Full Text] [Related]
36. Reply to: Glucarpidase for the Treatment of Methotrexate-Induced Renal Dysfunction and Delayed Methotrexate Excretion.
Scott JR; Crews KR
Pediatr Blood Cancer; 2016 Feb; 63(2):365. PubMed ID: 26488798
[No Abstract] [Full Text] [Related]
37. Life-threatening complications after high-dose methotrexate and the benefits of glucarpidase as salvage therapy: a cohort study of 468 patients.
Medrano C; Oberic L; Puisset F; Recher C; Larrieu-Ciron D; Ysebaert L; Protin C; Picard M; Perriat S; Chatelut E; Bertoli S; Huguet F; Tavitian S; Faguer S
Leuk Lymphoma; 2021 Apr; 62(4):846-853. PubMed ID: 33179543
[TBL] [Abstract][Full Text] [Related]
38. Understanding and managing methotrexate nephrotoxicity.
Widemann BC; Adamson PC
Oncologist; 2006 Jun; 11(6):694-703. PubMed ID: 16794248
[TBL] [Abstract][Full Text] [Related]
39. Glucarpidase for the management of elevated methotrexate levels in patients with impaired renal function.
Fermiano M; Bergsbaken J; Kolesar JM
Am J Health Syst Pharm; 2014 May; 71(10):793-8. PubMed ID: 24780487
[TBL] [Abstract][Full Text] [Related]
40. Extended duration of prehydration does not prevent nephrotoxicity or delayed drug elimination in high-dose methotrexate infusions: a prospectively randomized cross-over study.
Mikkelsen TS; Mamoudou AD; Tuckuviene R; Wehner PS; Schroeder H
Pediatr Blood Cancer; 2014 Feb; 61(2):297-301. PubMed ID: 24039194
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]